Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

The Role of Lipids in Hepatocellular Carcinoma.

Hayes CN, Zhang P, Chayama K.

In: Tirnitz-Parker JEE, editor. Hepatocellular Carcinoma [Internet]. Brisbane (AU): Codon Publications; 2019 Oct 24. Chapter 5.

2.

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K.

BMC Gastroenterol. 2019 Oct 24;19(1):169. doi: 10.1186/s12876-019-1092-z.

3.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K.

J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602. [Epub ahead of print]

PMID:
31584207
4.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN, Chayama K.

Clin J Gastroenterol. 2019 Aug 28. doi: 10.1007/s12328-019-01039-w. [Epub ahead of print]

PMID:
31463795
5.

Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals.

Johira Y, Hatooka H, Mori N, Fukuhara T, Takaki S, Shimomura Y, Imamura M, Hayes CN, Tsuji K, Chayama K.

Hepatology. 2019 Aug 20. doi: 10.1002/hep.30900. [Epub ahead of print] No abstract available.

PMID:
31432523
6.

Management of HCV patients in cases of direct-acting antiviral failure.

Hayes CN, Imamura M, Chayama K.

Expert Rev Gastroenterol Hepatol. 2019 Sep;13(9):839-848. doi: 10.1080/17474124.2019.1651642. Epub 2019 Aug 8.

PMID:
31392907
7.

Genomic characterization of early-stage esophageal squamous cell carcinoma in a Japanese population.

Urabe Y, Kagemoto K, Hayes CN, Nakamura K, Masuda K, Ono A, Tanaka S, Arihiro K, Chayama K.

Oncotarget. 2019 Jun 25;10(41):4139-4148. doi: 10.18632/oncotarget.27014. eCollection 2019 Jun 25.

8.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
9.

Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP.

Makokha GN, Abe-Chayama H, Chowdhury S, Hayes CN, Tsuge M, Yoshima T, Ishida Y, Zhang Y, Uchida T, Tateno C, Akiyama R, Chayama K.

Sci Rep. 2019 Jun 11;9(1):8462. doi: 10.1038/s41598-019-44934-5.

10.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.

Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K.

J Gastroenterol. 2019 Jul;54(7):650-659. doi: 10.1007/s00535-019-01558-w. Epub 2019 Feb 21.

PMID:
30790056
11.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
12.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.

Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2019 Mar;54(3):291-296. doi: 10.1007/s00535-018-1520-9. Epub 2018 Oct 17.

PMID:
30334096
13.

Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.

Hayes CN, Zhang P, Zhang Y, Chayama K.

Viruses. 2018 Sep 28;10(10). pii: E531. doi: 10.3390/v10100531. Review.

14.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K.

Virology. 2018 Dec;525:48-61. doi: 10.1016/j.virol.2018.08.020. Epub 2018 Sep 18.

PMID:
30240958
15.

Chromosomal Abnormalities in Human Lymphocytes after Computed Tomography Scan Procedure.

Shi L, Fujioka K, Sakurai-Ozato N, Fukumoto W, Satoh K, Sun J, Awazu A, Tanaka K, Ishida M, Ishida T, Nakano Y, Kihara Y, Hayes CN, Aikata H, Chayama K, Ito T, Awai K, Tashiro S.

Radiat Res. 2018 Oct;190(4):424-432. doi: 10.1667/RR14976.1. Epub 2018 Jul 24.

PMID:
30040044
16.

Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Med Virol. 2018 Dec;90(12):1834-1840. doi: 10.1002/jmv.25267. Epub 2018 Aug 13.

PMID:
30016555
17.

CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.

Nomura M, Tsuge M, Uchida T, Hiraga N, Kurihara M, Tsushima K, Fujino H, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Tanaka S, Chayama K.

J Viral Hepat. 2018 Dec;25(12):1555-1564. doi: 10.1111/jvh.12970. Epub 2018 Aug 29.

PMID:
29998562
18.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2018 Aug;99(8):1058-1065. doi: 10.1099/jgv.0.001091. Epub 2018 Jun 19.

PMID:
29916799
19.

Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2018;23(8):639-646. doi: 10.3851/IMP3240. Erratum in: Antivir Ther. 2019;23(8):709.

PMID:
29856363
20.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.

Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K; Hiroshima Liver Study Group.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157. doi: 10.1016/j.bbrc.2018.04.005. Epub 2018 Apr 13.

PMID:
29621544
21.

Retrospective Identification of Herpes Simplex 2 Virus-Associated Acute Liver Failure in an Immunocompetent Patient Detected Using Whole Transcriptome Shotgun Sequencing.

Ono A, Hayes CN, Akamatsu S, Imamura M, Aikata H, Chayama K.

Case Reports Hepatol. 2017;2017:4630621. doi: 10.1155/2017/4630621. Epub 2017 Dec 26.

22.

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients.

Kurihara M, Tsuge M, Murakami E, Mori N, Ohishi W, Uchida T, Fujino H, Nakahara T, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Chayama K.

Antivir Ther. 2018;23(3):239-248. doi: 10.3851/IMP3196.

PMID:
28933704
23.

Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.

Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K, Takaki S, Mori N, Honda Y, Arataki K, Takahashi S, Kira S, Tamura T, Masuda K, Nakamura T, Kikkawa M, Chayama K.

J Gastroenterol. 2018 Apr;53(4):548-556. doi: 10.1007/s00535-017-1380-8. Epub 2017 Aug 16.

PMID:
28815329
24.

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K.

PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017.

25.

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe-Chayama H, Furusho H, Shintani T, Kurihara H, Miyauchi M, Takata T, Arihiro K, Chayama K.

J Gastroenterol. 2018 Feb;53(2):269-280. doi: 10.1007/s00535-017-1368-4. Epub 2017 Jul 24.

PMID:
28741270
26.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00725-17. doi: 10.1128/AAC.00725-17. Print 2017 Sep.

27.

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.

J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25.

PMID:
28657143
28.

Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV.

Hayes CN, Chayama K.

Expert Rev Clin Pharmacol. 2017 Jun;10(6):583-594. doi: 10.1080/17512433.2017.1313111. Epub 2017 Apr 10. Review.

PMID:
28374641
29.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00183-17. doi: 10.1128/AAC.00183-17. Print 2017 Jun.

30.

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.

Miyaki E, Hiraga N, Imamura M, Uchida T, Kan H, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Serikawa M, Aikata H, Ochi H, Ishida Y, Tateno C, Ohdan H, Chayama K.

PLoS One. 2017 Mar 2;12(3):e0172412. doi: 10.1371/journal.pone.0172412. eCollection 2017.

31.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN, Tsuge M, Abe-Chayama H, Aikata H, Makokha GN, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2017 May;98(5):1040-1047. doi: 10.1099/jgv.0.000726. Epub 2017 May 25.

PMID:
28141486
32.

The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.

Hayes CN, Imamura M, Chayama K.

Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):103-113. doi: 10.1080/17474124.2017.1270205. Epub 2016 Dec 16. Review.

PMID:
27936974
33.

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Makokha GN, Ochi H, Amano H, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2017 Jun;52(6):746-753. doi: 10.1007/s00535-016-1279-9. Epub 2016 Nov 7.

PMID:
27822709
34.

Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.

Tsuge M, Hiraga N, Uchida T, Kan H, Miyaki E, Masaki K, Ono A, Nakahara T, Abe-Chayama H, Zhang Y, Naswa MG, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Chayama K.

J Gastroenterol. 2016 Nov;51(11):1073-1080. Epub 2016 Mar 4.

PMID:
26943168
35.

Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction.

Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Chayama K.

J Med Virol. 2017 Apr;89(4):665-671. doi: 10.1002/jmv.24679. Epub 2016 Oct 24.

PMID:
27602542
36.

Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.

Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Infect Dis. 2016 Dec 1;214(11):1687-1694. Epub 2016 Sep 20.

PMID:
27651415
37.

Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.

Chayama K, Hayes CN.

J Gastroenterol. 2017 Jan;52(1):125-126. doi: 10.1007/s00535-016-1252-7. Epub 2016 Aug 19. No abstract available.

PMID:
27541041
38.

Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.

Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.

J Gastroenterol Hepatol. 2017 Mar;32(3):645-650. doi: 10.1111/jgh.13511.

PMID:
27513614
39.

Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.

Hayes CN, Chayama K.

J Med Virol. 2017 Mar;89(3):388-396. doi: 10.1002/jmv.24659. Epub 2016 Nov 9. Review.

PMID:
27509053
40.

Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates.

Abe-Chayama H, Hayes CN, Chayama K.

Hepatology. 2016 Oct;64(4):1356-8. doi: 10.1002/hep.28751. Epub 2016 Aug 26. No abstract available.

PMID:
27480678
41.

The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.

Urabe A, Imamura M, Tsuge M, Kan H, Fujino H, Fukuhara T, Masaki K, Kobayashi T, Ono A, Nakahara T, Kawaoka T, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Maki N, Ohdan H, Chayama K.

J Gastroenterol. 2017 Mar;52(3):366-375. doi: 10.1007/s00535-016-1240-y. Epub 2016 Jul 15.

PMID:
27422771
42.

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K.

J Viral Hepat. 2016 Sep;23(9):708-17. doi: 10.1111/jvh.12551. Epub 2016 Jun 8.

43.

IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.

Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K; Hiroshima Liver Study Group.

Hepatol Res. 2017 Mar;47(3):E5-E13. doi: 10.1111/hepr.12715. Epub 2016 Apr 21.

PMID:
27027531
44.

HBV culture and infectious systems.

Hayes CN, Chayama K.

Hepatol Int. 2016 Jul;10(4):559-66. doi: 10.1007/s12072-016-9712-y. Epub 2016 Mar 2. Review.

PMID:
26935052
45.

MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma.

Hayes CN, Chayama K.

Int J Mol Sci. 2016 Feb 24;17(3):280. doi: 10.3390/ijms17030280. Review.

46.

Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Morio R, Hatooka M, Kan H, Fujino H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Urabe A, Yokoyama S, Nagaoki Y, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Ochi H, Chayama K; Hiroshima Liver Study Group.

Hepatol Res. 2016 Nov;46(12):1256-1263. doi: 10.1111/hepr.12681. Epub 2016 Apr 5.

PMID:
26916827
47.

Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients.

Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K.

Hepatol Res. 2016 Jul;46(8):758-64. doi: 10.1111/hepr.12621. Epub 2016 Feb 16.

PMID:
26574180
48.

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.

Uchida T, Hiraga N, Imamura M, Yoshimi S, Kan H, Miyaki E, Tsuge M, Abe H, Hayes CN, Aikata H, Ishida Y, Tateno C, Ellis JD, Chayama K.

Virus Res. 2016 Feb 2;213:62-68. doi: 10.1016/j.virusres.2015.11.010. Epub 2015 Nov 10.

PMID:
26569595
49.

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.

Kan H, Hiraga N, Imamura M, Hayes CN, Uchida T, Miyaki E, Tsuge M, Abe H, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antivir Ther. 2016;21(4):307-15. doi: 10.3851/IMP3009. Epub 2015 Nov 12.

PMID:
26562322
50.

Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones.

Murakami E, Tsuge M, Hiraga N, Kan H, Uchida T, Masaki K, Nakahara T, Ono A, Miki D, Kawaoka T, Abe H, Imamura M, Aikata H, Ochi H, Hayes CN, Akita T, Tanaka J, Chayama K.

J Infect. 2016 Jan;72(1):91-102. doi: 10.1016/j.jinf.2015.09.038. Epub 2015 Oct 26.

PMID:
26515673

Supplemental Content

Loading ...
Support Center